- CME/CE Activities
- Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression
This CME/CE activity is provided by PRIME Education, Inc. (PRIME®) and is accredited for a multi-disciplinary audience of health care practitioners. This activity is supported by contract number HHSA290201200021I from the Agency for Healthcare Research and Quality. User data collected through this activity will reside on PRIME's educational portal for use by AHRQ.
Updates on the Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression: A Feedback-Based Learning Activity
- Program Overview
- Faculty Biographies
- Accreditation Statements
- Post-Test & Evaluation
To Receive a Certificate for This Activity:
Activity DescriptionMajor depressive disorder (MDD) is a serious disease that affects more than 16 % of US adults. At any given time, 5%-9% of women and 2%-3% of men are likely to be clinically depressed. The management of such disorders depends upon first-generation antidepressants and more recently developed second-generation antidepressants. The second-generation antidepressants exhibit a more favorable adverse event profile yet similar efficacy when compared to the first-generation drugs thus play a more prominent role in managing patients with MDD.
The Agency for Healthcare Research and Quality (AHRQ) commissioned a comparative effectiveness review of published studies in 2011 updating an original report from 2007. The report focused on second-generation antidepressants and summarized the available evidence on the comparative efficacy, effectiveness, and harms of 13 second-generation antidepressants in managing patients with MDD, dysthymia, and subsyndromal depression. It also assessed the comparative efficacy and effectiveness for sustaining remission and for treating associated symptoms such as anxiety, insomnia, or neurovegetative symptoms. Based on the evidence obtained from the AHRQ systematic reviews, this interactive video challenges health care professionals to think critically about optimal patient-centered therapies for managing MDD.
At the conclusion of this activity, the participant should be able to:
- Compare the effectiveness and efficacy of antidepressants in treating depressive symptoms in adults
- Assess the benefits and harms of antidepressants among certain adult patient subgroups
- Apply the findings of the systematic review to improve outcomes for adult patients through patient-centered care
This CME activity is designed to meet the educational needs of physicians, physician assistants, nurse practitioners, pharmacists, nurses, case managers and health education specialists.
Method of Participation
To receive a certificate for this activity, you should:
- Complete the learner assessment pretest
- View the entire activity online
- Complete an online evaluation & post-test
- Print your certificate online
The estimated time to complete this activity, including review of the materials, is 1.0 hour.
Term of Approval
June 30, 2012 through June 29, 2014. Original release date: June 30, 2012.
Acknowledgement of Support
There is no fee for this CME/CE activity. This activity is sponsored by PRIME Education, Inc (PRIME®) and funded under contract HHSA290201200021I from the Agency for Healthcare Research and Quality (AHRQ), U.S. Department of Health and Human Services (HHS).
Faculty Biographies and Disclosures
Bradley N Gaynes, MD, MPH
Professor of Psychiatry
Department of Psychiatry
University of North Carolina School of Medicine
Chapel Hill, NC
Carolyn LePage, PhD, ARNP
Barry University School of Nursing
Miami Shores, FL
Heidi Wynn Maloni, PhD, ANP-BC, CNRN, MSCN
National Clinical Nursing Director
Department of Neurology
Multiple Sclerosis Center of Excellence, East
Veterans Affairs Medical Center
Trinity Nursing Program School of Professional Studies
Trinity Washington University
Clinical Preceptor and Instructor
Advanced Practice Programs
The Catholic University of America School of Nursing
M David Rudd, PhD, ABPP
Distinguished University Professor
University of Memphis
Michele B Kaufman, PharmD, CGP, RPh
President, PRN Communications Inc.
Editor, Pharmacovigilance Forum, P&T Journal
Touro College of Pharmacy
New York, NY
Wanda F Carter, MPH, CHES
Adjunct Professor, Kaplan University Master of Public Health Program
Adjunct Professor, Axia College (U of Phoenix) Health Care Administration Program
Adjunct Professor, LA College International Health Care Administration Program
Adjunct Professor, Ashford University Health Care Administration Program
PHPS Alumnus, CDC Scientific Education and Professional Development Program Office
Joyce M Knestrick, PhD, CRNP, FAANP
Coordinator of Graduate Education
Frontier School of Midwifery and Family Nursing
Certified Family Nurse Practitioner
The Primary Care Center
Mt Morris, PA
Larry Culpepper, MD, MPH
Professor and Chairman of Family Medicine
Boston University School of Medicine
Boston Medical Center
Pamela Feinberg-Rivkin, RN, BSN, CCM, CRRN, ABDA
Independent Care Manager
Farmington Hills, MI
Scott A Strassels, PharmD, PhD, BCPS
Healthcare Policy and Economic Outcomes
St. Louis, MO
Physician Credit Designation Statement
PRIME Education, Inc. (PRIME®) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
PRIME® designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Physician Assistant Accreditation Statement
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME. Physician assistants may receive a maximum of 1.0 hours of Category I credit for completing this program.
Psychologist Accreditation Statement
PRIME Education, Inc. (PRIME®) is approved by the American Psychological Association to sponsor continuing education for psychologists. PRIME® maintains responsibility for this program and its content.
Nurse Practitioner Accreditation Statement
PRIME Education, Inc (PRIME®) is approved as a provider of Nurse Practitioner Continuing Education by the American Association of Nurse Practitioners. Provider number: 060815. This program is accredited for 1.0 contact hour. Program ID# CER34.
This program was planned in accordance with AANP CE Standards and Policies and AANP Commercial Support Standards.
Pharmacist Accreditation Statement
PRIME® is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This curriculum has been approved for 1.0 contact hour (0.1 CEUs) by PRIME®. The Universal Activity Number for this program is 0255-0000-12-031-H01-P. This learning activity is Knowledge-Based.
Nurse Accreditation Statement
PRIME Education, Inc. (PRIME®) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
PRIME® designates this activity for 1.0 contact hour.
Certified Health Education Specialist Accreditation Statement
Sponsored by PRIME Education, Inc. (PRIME®), a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc.
This program is designated for Certified Health Education Specialists (CHES) to receive up to 1.0 Category I contact hours in health education.
CHES Provider Number: MEP3774
|Faculty Name ||Advisory Board||Consultant||Grants / Research||Salary / Contractual||Supported Promotional Education||Stock / Shareholder||Other Financial Support|
|Bradley N Gaynes, MD, MPH
|Carolyn LePage, PhD, ARNP
|Heidi Wynn Maloni, PhD, ANP-BC, CNRN, MSCN
|M David Rudd, PhD, ABPP
|Michele B Kaufman, PharmD, CGP, RPh
|Wanda F Carter, MPH, CHES
|Joyce M Knestrick, PhD, CRNP, FAANP
|Larry Culpepper, MD, MPH
|AstraZeneca Pharmaceuticals LP, Labopharm, Pfizer Inc., Trovis Pharmaceuticals, LLC||None||None||None||Merck for unbranded presentations re: federally supported research about approaches to reduce hospital readmissions||None||Labopharm|
|Pamela Feinberg-Rivkin, RN, BSN, CCM, CRRN, ABDA
|Scott A Strassels, PharmD, PhD, BCPS
|Chris R Prostko, PhD|
Scientific Program Director
|Lynn Goldenberg, RN, BSN|
Director of Accreditation & Compliance
PRIME Education Inc (PRIME®) endorses the standards of the ACCME, as well as those of the AANP, ANCC and ACPE, that require everyone in a position to control the content of a CME/CE activity to disclose all financial relationships with commercial interests that are related to the content of the CME/CE activity. CME/CE activities must be balanced, independent of commercial bias and promote improvements or quality in healthcare. All recommendations involving clinical medicine must be based on evidence accepted within the medical profession.
A conflict of interest is created when individuals in a position to control the content of CME/CE have a relevant financial relationship with a commercial interest which therefore may bias his/her opinion and teaching. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, stocks or other financial benefits.
PRIME® willidentify, review and resolve all conflicts of interest that speakers, authors, course directors, planners, peer reviewers, or relevant staff disclose prior to an educational activity being delivered to learners. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of a presentation. Disclosure information for speakers, authors, course directors, planners, peer reviewers, and/or relevant staff are provided with this activity.
Presentations that provide information in whole or in part related to non FDA approved uses of drugs and/or devices will disclose the unlabeled indications or the investigational nature of their proposed uses to the audience. Participants should refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. Participants should verify all information and data before treating patients or employing any therapies prescribed in this educational activity. The opinions expressed in the educational activity are those of the presenting faculty and do not necessarily represent the views of PRIME®, the ACCME, AANP, ACPE, ANCC and other relevant accreditation bodies.
Content validation methods are consistently utilized by PRIME® to ensure that all program content is evidence-based, fair-balanced, and developed with scientific rigor and integrity. All clinical recommendations are based on evidence accepted within the medical profession. All scientific research referred to, reported or used to support a clinical recommendation conforms to accepted standards of experimental design, data collection and analysis. In addition to review of content by course directors and expert faculty, content is also validated through independent peer reviewers selected for their expertise in the content area, as well as their experience in the intended audience. All peer reviewers, planners, course directors, faculty and relevant staff utilized by PRIME® complete disclosures which are related to their role in the educational activity.
PRIME®is committed to providing access to our CME programs for individuals with disabilities as identified in Section 508 of the Rehabilitation Act for all web-based programs. This website is 508 compliant.
To access the activity, please complete this brief Pretest.
Post-Test & Evaluation
You must access the activity before receiving credit!
Clinician & Consumer Summaries on Adult Depression
Download these free summaries for your reference and/or patient handouts. You may also order bulk copies free of charge from the AHRQ Publication Clearinghouse below.